Targeted treatment of mature T-cell lymphoma
A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.
1. A method of treating a patient suffering from aggressive peripheral T-cell lymphoma (PTCL), comprising administering to a PTCL not otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma (ALCL), or angioimmunoblastic T-cell lymphoma (AITL) patient in need of treatment an effective amount of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d] [3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof,
wherein the administering comprises:
administering a loading dose of 75 mg/dose of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d] [3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof two or three times per week for at least one week of a 28 day cycle; followed by
administering a maintenance dose of 50 mg/dose of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d] [3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof three times per week.
2. The method of claim 1 , wherein the loading dose of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d] [3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof is administered every other day over a five day period followed by two days without administration (T.I.W.).
3. The method of claim 1 , wherein the maintenance dose of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof is administered T.I.W.
4. The method of claim 1 , wherein:
2 or 3 loading doses are administered over the course of one week;
4 to 6 loading doses are administered over the course of two weeks; or
8 to 12 loading doses are administered over the course of four weeks.
5. The method of claim 1 , wherein the administration is oral.
6. The method of claim 1 , wherein the patient has advanced or metastatic PTCL-NOS, ALCL, or AITL.
7. The method of claim 1 , wherein the maintenance dose is administered over any remaining days of the 28 day cycle.
8. The method of claim 7 , wherein, after the maintenance dose is administered over any remaining days of the 28 day cycle, the maintenance dose is administered over one or more additional 28 day cycles.
9. The method of claim 1 , further comprising administering 1 to 50 mg/dose of a corticosteroid during administration of the loading dose.
10. The method of claim 9 , wherein the corticosteroid is selected from the group consisting of hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, prednisone, methylprednisolone, and dexamethasone.
11. The method of claim 8 , wherein:
2 or 3 loading doses are administered over the course of one week;
4 to 6 loading doses are administered over the course of two weeks; or
8 to 12 loading doses are administered over the course of four weeks.
12. The method of claim 1 , wherein:
2 or 3 loading doses are administered over the course of one week; or
4 to 6 loading doses are administered over the course of two weeks; or
8 to 12 loading doses are administered over the course of four weeks; and
the maintenance dose is administered three times per week.
13. The method of claim 12 , further comprising administering 1 to 50 mg/dose of a corticosteroid during administration of the loading dose.
14. The method of claim 13 , wherein the corticosteroid is selected from the group consisting of hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, prednisone, methylprednisolone, and dexamethasone.